GlobeNewswire

Cisco Releases New Developer Capabilities Across Its Intent-Based Networking Platform

Dela

ORLANDO, Fla., June 12, 2018 (GLOBE NEWSWIRE) -- CISCO LIVE - Cisco today announced that it has released new developer capabilities across its intent-based networking platform. These advancements underscore Cisco's continued progress in delivering an open, programmable platform that spans the entire network, from campus to data center, branch to edge. By providing an open network, Cisco is empowering 500,000 developers, 60,000 partners and three million network engineers to innovate upon the platform.

Intent-based networking represents a fundamental shift in the way networks are built and managed. Moving away from the manual, time-intensive methods by which networks are traditionally managed, these modern networks capture business intent and translate it into network policies. These policies are then automatically activated across the entire infrastructure, with the assurance that the business intent was delivered as planned.

"Intent-based networking represents the next generation of open, IP-based systems that we've seen can change the actual fabric of society," said David Goeckeler, executive vice president and general manager of Cisco's Networking and Security Business. "Cisco is building an open architecture that will power an ecosystem to accelerate intent-based networking innovation. Already, our customers and partners are creating value from their networks in ways they thought weren't possible as recently as one year ago."

Announcing the DNA Center platform 
Today, Cisco is releasing new developer tools and open APIs into Cisco DNA(TM) Center - the command and control center for campus, branch and edge intent-based networks. DNA Center turns the network from a combination of hardware devices into a single system. With the availability of network-wide APIs, Cisco now allows developers to easily program this system, tapping into all of the analytics and insight the network can provide.

With a rich API catalog, DNA Center allows customers to protect and inform their business like never before.

Elevating network intelligence into business operations: DNA Center helps enable developers to program the network as a single system through intent-based APIs. Now, developers can more easily create a new generation of network-aware applications, and partners can integrate the network into business processes.

Streamline IT processes across functions: DNA Center helps enable network IT administrators to exchange information to automate processes across IT systems through software adapters. Now, IT can move resources from operation to innovation.

Managing multi-vendor networks: DNA Center gives developers and partners the flexibility to support multi-vendor networks via a software developer kit (SDK). This allows customers to simplify the complexity of heterogeneous networks and manage them consistently, as a single system. 

Already, 15 Cisco partners have built innovative solutions on the DNA Center platform and are demonstrating them at Cisco Live. 

Announcing the largest developer community for intent-based networking 
Cisco is also announcing that its developer community, DevNet, has surpassed 500,000 members. In building this large and active community, Cisco has introduced a new source of innovation as the network becomes increasingly programmable.

Today, Cisco is announcing three new developer initiatives to fuel its innovation ecosystem:

  • DevNet Ecosystem Exchange makes it easy to find and share an application or solution built for Cisco platforms. Business leaders and developers alike can use this online portal to discover partner solutions that span all Cisco platforms and products. It contains over 1,300 solutions.

  • DevNet Code Exchange gives developers a place to access and share software to quickly build next-generation applications and workflow integrations. A curated list of sample code, adaptors, tools, and SDKs is available on GitHub and written by Cisco and the DevNet community. Code Exchange spans Cisco's entire portfolio and is organized according to Cisco platform and product areas.

  • DevNet DNA Developer Center is a one-stop-shop for developers to build applications and integrations on the DNA Center platform. It provides comprehensive resources, capabilities, use cases and learning materials for developers.

Availability, Services and Support

  • The new DNA Center capabilities are scheduled to be available during the summer of 2018. Customers can purchase these new capabilities from Cisco and its partners via existing subscription offers.

  • DevNet's Ecosystem Exchange, Code Exchange, and DNA Developer Center are available now.

  • Cisco and its partners offer a full lifecycle of services to help customers streamline the journey to truly intent-based networks.

Additional Information

About Cisco
Cisco (NASDAQ:CSCO) is the worldwide technology leader that has been making the Internet work since 1984. Our people, products, and partners help society securely connect and seize tomorrow's digital opportunity today. Discover more at newsroom.cisco.com and follow us on Twitter at @Cisco.

Cisco, the Cisco logo, Cisco and Cisco IOS Systems are registered trademarks or trademarks of Cisco Systems, Inc. and/or its affiliates in the United States and certain other countries. All other trademarks mentioned in this document are the property of their respective owners. The use of the word partner does not imply a partnership relationship between Cisco and any other company. This document is Cisco Public Information.

Press Relations: 
Gareth Pettigrew
+1-250-240-0638
gpettigr@cisco.com

RSS Feed for Cisco: http://newsroom.cisco.com/rss-feeds




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Cisco via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in October and November22.10.2018 16:00Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Announces Upcoming Investor Events in October and November Immunicum AB (publ; IMMU.ST) announced today that the Company will participate in and host investor events in October and November. At all events Carlos de Sousa, CEO of Immunicum, and other members of the management team, will provide a corporate presentation and be available for a question and answer session. BioStock Life Science Summit Date: October 25, 2018 Presentation Time: 18.50 Central European Time Venue: Medicon Village, Scheelevägen 2, Building 302-auditorium, Lund, Sweden Registration Link: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicum Investor Event - Gothenburg Date: October 29, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venue: First Hotel G, Nils Ericsonplatsen, 411 03 Gothenburg, Sweden Immunicum Investor Event - Stockholm Date: October 30, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venu

Immunicum AB (publ) meddelar kommande investerarevent under oktober och november22.10.2018 16:00Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) meddelar kommande investerarevent under oktober och november Immunicum AB (publ; IMMU.ST) meddelar i dag att bolaget kommer att anordna och delta i investerarträffar under oktober och november. Vid samtliga event kommer Carlos de Sousa, Immunicums VD, och övriga medlemmar av ledningsgruppen, att hålla en presentation av bolaget och vara tillgängliga för att svara på frågor. BioStock Life Science Summit Datum: 25 oktober 2018 Presentationstid: Kl. 18.50 CET Plats: Medicon Village, Scheelevägen 2, byggnad 302 - hörsalen, Lund Länk för registrering: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicums investerarevent - Göteborg Datum: 29 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: First Hotel G, Nils Ericsonplatsen, 411 03, Göteborg Immunicums investerarevent - Stockholm Datum: 30 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: Ingenjörshuset Citykonferensen, Plan 1, Malmski

Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress22.10.2018 12:45Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress -- Intratumoral behandling med ilixadencel, en cellbaserad, lagringsbar immunaktiverare, ger en synergistisk antitumöreffekt och förstärker effekten av behandling med anti-PD-1 och anti-CD137 i djurmodeller -- Immunicum AB (publ; IMMU.ST) presenterar under 2018 års ESMO kongress (European Society for Medical Oncology) prekliniska resultat som visar en synergistisk anti-tumöreffekt när bolagets ledande produkt ilixadencel ges i kombination med en checkpointhämmare eller immunaktiverare. Resultaten från studien, som presenteras på en poster, visar att intratumoralt administrerat ilixadencel kan förstärka anti-tumörsvar och överlevnad vid behandling med checkpointhämmare eller immunaktiverare. Detta visar på potentialen hos ilixadencel att bli en komplementerande verkningsmekanism till flera olika framtida im

Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 201822.10.2018 12:45Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018 -- Intratumoral treatment with ilixadencel, an off-the-shelf cell-based immune primer, provides synergistic anti-tumor effect and enhances efficacy of anti-PD-1 and anti-CD137 treatment in animal model -- Immunicum AB (publ; IMMU.ST) announced today the presentation of preclinical results that showed anti-tumor synergy between its lead product ilixadencel and a checkpoint inhibitor or an immune enhancer in a poster at the European Society for Medical Oncology (ESMO) 2018 Congress. The results of the study highlight the ability of intratumoral ilixadencel to enhance anti-tumor response and survival of systemic checkpoint inhibitors (anti-PD-1) or immune enhancers (anti-CD137/4-1BB). This emphasizes the potential for ilixadencel in multiple future immuno-oncology combination strategies by incorporating complementary mech

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum